

Index

A

acute myocardial infarction 209
admission rate bias 74
adverse events 204
age-specific mortality 24
agreement rate 98, 181
allele 118
allocation concealment 196
 α -error 69
Alvarado score 187–188
antagonism 93
Apolipoprotein E (APOE) 125
area under the curve (AUC) 170
association
 case-control design 125
 collaboration 128–129
 defined 124
 for continuous outcomes 41–43
 for dichotomous outcomes 34–41
 genome-wide 126–128
 health outcomes and explanatory factors 32–34
 linkage disequilibrium 125
 linkage equilibrium 125–126
 population stratification 128
attack rates 136, 144
attributable risk (AR) 35
attrition 54
attrition bias 72
autocorrelation coefficients 141

B

basic reproduction number 154–156
Bayes' theorem 175–176
Berkson's fallacy 59, 74
 β -error 69
bias 66, 69
bias away from the null value 70
bias toward the null value 70
biobank 129
birth outcomes 210
Bland-Altman plot 183–184
blinded 54
blinding 196, 197
block randomization 197
block size 197
breast cancer 120
 gene 124

C

calibration line 99
cardiovascular disease, risk factors 32, 33
carryover effects 198
case-control studies 52, 58–61, 144–146
case definition 140, 148–149
case fatality 25–26
causal diagram 91, 92, 105
causality 102
 definition 106–107
 Hill criteria 110–111
 individual vs. population level 111–112
 interpretation 108–110
 sufficient and necessary causes 107–108
cause-specific mortality 25
Cesarean section (CS) 185–186
childhood obesity prevention program 201
cholera 8
chromosomes 118
citation screening 212
clinical diversity 214
clinicaltrials.gov 194
closed populations 17
cluster randomized design 201
cluster randomized trial 201
clusters and outbreaks
 basic reproduction number 154–156
 simulation models 153–154
 surveillance using non-medical data 153
Cohen's kappa 98, 181–183
cohort 18
cohort studies 52, 54–58, 143
collider 92
collider bias 92, 105
comorbidity 25
complex phenotypes 119
compliance 54
comprehensive search strategy 210–212
conceptual definition 97
conceptual scale 97
confidence interval (CI) 67–69
confounders 49, 195
confounding 4, 71, 76
confounding by contraindication 196
confounding by indication 81, 196
consent procedure 194
contamination 201
content validity 166
controlled vocabulary 211

correlation 183–184
correlation coefficient 42, 183
cost-effectiveness 192
counterfactual 50
course of disease 14
COVID-19, 2, 152
Cox proportional hazards 37
criterion validity 166
crossover design 198–199
cross-sectional studies 52, 61–62
crude association 78
crude mortality 23–24
cumulative incidence 21–22
cumulative incidence ratio (CIR) 36

D

DALYs. *see* disability-adjusted life years (DALYs)
data from RCTs
 intention-to-treat analysis 203
 per-protocol analysis 203
 randomization 202–203
 sequential analyses 203
deduction 6
"de novo" mutation 118
dependent variable 4
diagnosing diabetes 168–169
diagnosis 161
diagnostic factors 3
diagnostic information 161–163
diagnostic odds ratio (DOR) 177–178
diagnostic research
 guidelines for 184
 phases 163
diagnostic study 48
diagnostic tests
 reproducibility of 165–166
 sources of 163–165
 validity of 166
diagnostic variability, sources of 163–165
differential misclassification 56, 195
differential selection 71
Directed Acyclic Graph (DAG) 92, 105
direct standardization 24
disability-adjusted life years (DALYs) 27
disease 14
 definition 14–17
 frequency 17
disease cluster 137
dispersion parameter 136

document search 212
 domain 95
 Down syndrome 118
 dynamic transmission models 153

E

early warning, surveillance for 137–141
 ecological fallacy 62
 ecological study 52, 62
 effectiveness 195
 effective reproduction number 155
 effect modification 4, 92, 192
 effect of dexamethasone 193
 efficacy 195
 eligibility criteria, RCT 192
 empirical cycle 5
 empirical scale 97
 epidemic 134
 epidemic curve 142–143
 epidemiological fraction 3
 epidemiological function 14
 epidemiology 2
 characteristics 2
 definition 2
 empirical cycle 5–6
 explanatory factors 3–4
 frequency measures 3
 function 4
 health outcomes 2–3
 historical examples 7–9
 modern 9–10
 specialization 10
 etiological factors 3
 etiological fraction (EF) 38
 etiological model 105
 etiological research 102
 etiological study 48
 evidence-based medicine (EBM) 209
 experimental research 52
 expert validity 166
 explanatory factors 3
 explanatory trial 195
 exposure measurement 55
 external validation 185
 external validity 95
 extrapolation 96
 selection 96–97
 study sample 95–96
 extrapolation 96

F

face validity 166
 factorial design 199–200
 falsifiability 5

familial aggregation 119
 familial relative risk 120
 family-based cohorts 120
 family-based control group 60
 family-based studies 122–124
 fixed-effects model 214
 follow-up period 55
 follow-up time 18
 forensic epidemiology 113
 frequency
 cohort 18
 concept of time 18–19
 disease 14–17
 incidence 20–23
 mortality 23–27
 of health outcomes 14
 populations 17–18
 prevalence 19–20
 frequency matching 60
 full-text screening 212

G

generalizability 95
 genetic association studies 124
 genetic epidemiology
 allele 118
 association studies (*see* association studies)
 chromosomes 118
 defined 118
 “de novo” mutation 118
 familial aggregation 119
 family-based studies 122–124
 genome-wide linkage analysis (GWLA) 119
 haplotypes block 118
 homologous 118
 locus 118
 Mendelian randomization 129–130
 molecular epidemiology 118
 monogenetic disorders 118
 multifactorial or complex phenotypes 119
 mutant form 118
 mutation 118
 penetrance 119
 phenotype 118
 pleiotropy 119
 polymorphism 118
 precision medicine 129
 reporting guidelines 131
 research 119–120
 terminology 118–119
 variant 118
 wild type 118
 genetic heterogeneity 119

genetic variants 118
 genome-wide association studies (GWAS) 126–128
 genome-wide linkage analysis (GWLA) 119
 genotype 118
 geographical correlation studies 62
 geographical information systems (GIS) 141
 gold standard 98, 166

H

haplotypes block 118
 hazard rate 22, 37
 hazard rate ratio 37
 health equity 10
 health indicator 14
 health outcomes 2–3
 association 32–34
 continuous measures of 27–28
 definition 14
 in measurement errors 195
 healthy life expectancy 27
 healthy worker effect 72
 herd immunity 156
 heterogeneity 215
 historical cohort study 56
 homologous chromosomes 118
 hospital-based control group 59
 human traits 121
 hypotheses 6

I

ID. *see* incidence density (ID)
 illness 14
 incidence 20
 and prevalence 21
 incidence density (ID) 18, 22–23
 incidence density ratio (IDR) 36
 incidence rate 22
 incubation period 136
 independent variables 4
 index-event bias 105
 indirect standardization 24–25
 individual matching 60
 induction 5
 infectious disease epidemiology, 134, 136
 infectious period 136
 information bias 49, 70, 71, 74
 informed consent 53
 intention-to-treat analysis 197, 203
 interim analysis 203
 intermediary factor 76

intermediate outcomes 194
 internal validation 185
 internal validity 49
 International Classification of Diseases (ICD) 15
 interobserver agreement 166
 interobserver variability 98, 166
 interpercentile range 28
 inter-rater reliability 166
 interventions, assessing harms of 203–204
 intervention study 48, 192
 intra-class correlation coefficient (ICC) 184
 intracluster correlation coefficient (ICC) 201
 intra-observer variability 98, 166
 in-vitro fertilization (IVF) 11
 I^2 statistics 215

L

life expectancy 26
 lifetime prevalence 19
 likelihood ratio 173–174
 likelihood ratio of a negative test result 173
 likelihood ratio of a positive test result 173
 linear regression 43
 linkage 122
 linkage analysis 122–124
 linkage disequilibrium (LD) 125
 linkage equilibrium (LE) 125–126
 living systematic reviews 218
 locus 118
 logarithmic regression 43
 logistic regression 44
 log-linear models 91
 log-odds score (LOD score) 122
 longitudinal study 52

M

Mantel-Haenszel estimate 90
 marketing authorization 194
 matching 55, 60, 85–86
 mean 27
 difference of, 41
 measurement errors 195
 median 27
 mediation 76
 Medical Subject Headings (MeSH), 211
 membership bias 73

Mendelian randomization 129–130
 meningitis outbreak, in Sudan 154
 meta-analysis 213–215
 meta-regression 215
 methodological diversity 214
 minimization 197
 misclassification 74
 mode 27
 modern epidemiology 9–10
 molecular epidemiology 118
 monogenetic disorders 118
 mortality 23–27
 multi-causality 105
 multifactorial phenotypes 119
 multiple tests
 parallel tests 179–180
 serial testing 178–179
 multivariable modeling 90
 multivariable regression analysis 90
 mutant form 118
 mutation 118

N

natural course of disease 195
 negative bias 70
 nested case–control study 57
 network meta-analysis 213
 new infectious disease 2
 N-of-1 experiment 202
 non-compliance 54
 non-differential misclassification 74
 non-differential selection 71
 non-respondent bias 74
 non-systematically collected adverse events 204

O

observational studies 52
 observational study designs
 case–control study 58–61
 cohort study 54–58
 cross-sectional study 61–62
 ecological study 62
 observed effect 194–195
 external factors 195
 observer bias 197
 odds ratio (OR) 37–38
 open populations 17
 operational definition 97
 optimism 187
 oral contraceptives (OCP) 11
 oral glucose tolerance test (OGTT) 168
 outbreak epidemiology

 defined 134
 interpreting data on supposed outbreaks 151–152
 other approaches 152–156
 stepwise approach to outbreak investigation 147–151
 study designs for research into outbreaks 141–147
 surveillance for early warning 137–141
 outcome measurement 55
 outcome-reporting bias 217
 outcomes 192
 overcorrection 92
 overfitting 187
 overviews of reviews 218

P

pairwise meta-analysis 213
 pandemic 134
 parallel testing 179–180
 Pearson's correlation coefficient 183
 PECO 48
 peer-based control group 59–60
 penetrance 119
 performance bias 197
 period effect 198
 period prevalence 19
 per-protocol analysis 203
 phase I research 194
 phase II research 194
 phase III research 194
 phenotype 118
 PICO 48
 pivotal trials 194
 placebo 54
 placebo effect 195
 pleiotropy 119
 point prevalence 19
 point source outbreak 143
 polymorphism 118
 population attributable risk (PAR) 38–39
 population-based control group 59
 Population, Interventions, Comparators, and Outcomes (PICO) framework 209
 populations
 closed and open 17–18
 cohort 18
 population stratification 128
 positive bias 70
 posterior probability 174
Post hoc ergo propter hoc 102
 post-marketing surveillance 194, 204
 potential bias 70
 potential impact fraction (PIF) 39
 power 69

Pragmatic-Explanatory Continuum Indicator Summary (PRECIS) tool 196
 pragmatic trial 195
 precision 66
 vs. sample size 69
 precision medicine 129
 prediction model
 defined 185
 performance of 187
 prediction research 103
 predictive value 174–175
 pre-stratification 81
 presumed cause 49
 prevalence 17, 19
 incidence and 21
 prevalence predicting 163
 prevention paradox 39
 primary prevention 114
 prior probability 174
 prognosis 161
 prognostic factors 3
 prognostic information 161–163
 prognostic odds ratio (POR) 186
 prognostic research 184
 data to quantify 186–187
 design 185–186
 guidelines for 187
 overfitting 187
 phases 184–185
 prognostic study 48
 proportional hazards model 91
 proportional mortality 26
 publication bias 217
 p-value 68

Q

qualitative bias 70
 qualitative synthesis 214
 quality-adjusted life years 27
 quality of life 17
 quantitative bias 70

R

random-effects meta-analysis 214
 random errors 66, 67
 randomization 53, 78
 to create comparability 196–197
 data from RCTs 202–203
 defined 196
 randomized crossover trial
 on asthma outcomes 200
 defined 198

dietary quality of grocery purchase 199
 randomized experiment 52–54
 range 28
 rapid review 218
 rapid warning without false alarms 141
 recall bias 59, 76
 receiver operating characteristic (ROC) curve 169–173
 reference standard 98
 referral bias 74
 regression analysis 43–44
 regression coefficient 42, 186
 regression to mean 195
 relative risk (RR) 35–37
 reliability 97
 reliable 66
 reproducibility 97, 165
 reproducibility measurement of
 diagnostic tests
 agreement rate 181
 Cohen's kappa 181–183
 correlation 183–184
 reproduction number 136
 research question
 blinding to maintain comparability
 right to end 197–198
 cluster randomized design 201
 crossover design 198–199
 efficacy vs. effectiveness 195–196
 factorial design 199–200
 N-of-1 experiment 202
 observed effect 194–195
 randomization to create
 comparability 196–197
 residual confounding 75
 responsive 97
 restriction 55, 85
 risk factors 3
 risk of bias 212, 213

S

sampling error 67
 scoping reviews 218
 scurvy/scorbutus 2
 secondary attack rate 136
 secondary prevention 114
 selection bias 56, 70, 71
 selective dropout 72
 sensitivity 167–169
 sentinel system 138
 sequential analysis 203
 serial testing 178–179
 sickness 14
 Simpson's paradox 76

single nucleotide DNA variants (SNVs) 125
 single nucleotide polymorphisms (SNPs) 125
 source 95
 source population 48, 95, 192
 specific agreement 183
 specificity 167–169
 stability 166
 standard deviation (SD) 28
 standard error (SE) 67
 standardization 90
 standardized mean difference (SMD) 41
 standardized mortality 24
 standardized mortality ratio (SMR) 25
 statistical heterogeneity 215
 statistically significant effect 68
 statistical tests 68
 stepwise approach to outbreak investigation
 step 1: establish that there is an outbreak 147
 step 2: verify the diagnosis 148
 step 3: construct the case definition 148–149
 step 4: identify the “right” cases 149
 step 5: describe the incidence of the cases in terms of time, place, and personal characteristics 149
 step 6: formulate hypotheses 149
 step 7: conduct an initial analytical study 149
 step 8: adjust the hypotheses and carry out additional research 149–150
 step 9: implement control and prevention measures 150
 step 10: initiate or maintain surveillance 150–151
 step 11: make findings known to the public 151
 stratification 197
 stratified analysis 78, 90
 stratum-specific association 78
 study design
 attack rates 144
 case-control studies 144–146
 classifications 50–52
 cohort studies 143
 epidemic curve 142–143
 observational 55–62
 randomized experiment 52–54
 research question 48–50
 risks to individuals and populations 146–147
 study population 95
 study population definition 55

- study sample 49
- subgroup analysis 215
- surrogate outcomes 194
- survival 26
- survival bias 56
- survival curve 26–27
- switch-over bias 70
- syndrome surveillance 140
- synergism 93
- systematically collected adverse events 204
- systematic errors 66
- systematic measurement error 74
- systematic reviews 51
 - analyze and synthesize data 213–216
 - defined 208
 - extract data and assess risk of bias 212–213
 - frame the research question and decide on eligibility criteria 209–210
 - interpret findings and writing report 217
 - search for and select studies 210–212

T

- the target population 48
- tertiary prevention 114
- test-retest reliability 166
- theory 5
- thiopurine methyltransferase (TPMT) gene 129
- time-trend studies 62
- toxic shock syndrome (TSS) 145–146
- transmission rates 136, 146
- twins studies 121
- type 2 diabetes
 - GWAS for 128
 - risk of 126
- type I error 69
- type II error 69

U

- UK Biobank 57–58
- undercorrection 92
- US National Library of Medicine (NLM) 211

V

- valid 66
- validity 66, 69
- validity measurement of diagnostic tests
 - Bayes' theorem 175–176
 - diagnostic odds ratio 177–178
 - likelihood ratio 173–174
 - multiple tests 178–180
 - predictive value 174–175
 - receiver operating characteristic (ROC) curve 169–173
 - sensitivity and specificity 167–169
- variants
 - defined 118
 - fitness 119
- volunteer bias 74

W

- washout phase 198
- whooping cough 138–139
- wild type 118
- withdrawal bias 74
- WTCCC 128

